Compare FTEL & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | ENVB |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.0M |
| IPO Year | 2023 | N/A |
| Metric | FTEL | ENVB |
|---|---|---|
| Price | $3.07 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | ★ 425.2K | 53.6K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | ★ 45.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,200,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $2.91 | $3.50 |
| 52 Week High | $1,427.20 | $61.18 |
| Indicator | FTEL | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 47.31 |
| Support Level | $2.96 | $3.76 |
| Resistance Level | $3.85 | $4.33 |
| Average True Range (ATR) | 0.32 | 0.27 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 76.48 | 80.45 |
Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.